Invisalign maker Align Technology to invest Rs 1,800 crore in Hyderabad plant

US firm Align Technology will invest Rs 1,800 crore in Hyderabad for its first Indian manufacturing plant. This facility will be the company's fourth globally. It is expected to create over 300 jobs. The investment will boost Align Technology's existing operations in the city. The new plant will support its worldwide production of clear aligners.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BphLCdz
via IFTTT

Read More

Pregabalin moved to Schedule H1 as centre cracks down on drug misuse

Pregabalin, a nerve pain medication, now faces stricter controls. The Union health ministry has moved it to Schedule H1. This change aims to curb its misuse, especially among youth. Previously available over-the-counter, it now requires strict prescriptions. Pharmacies must maintain records and display prominent warnings.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Si5YHum
via IFTTT

Read More

ICMR replaces old system with single window approval for medical studies

The Indian Council of Medical Research has introduced a unified ethics approval process for multicentre medical studies, replacing the previous fragmented, site-by-site system. This significant reform aims to expedite research timelines, reduce costs, and expand participation to rural and vulnerable populations, fostering more representative and robust health policy evidence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KnMQj3G
via IFTTT

Read More

Eli Lilly’s obesity drug shows up to 30% weight loss in trial

Eli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body weight. This once-weekly injection targets multiple hormone receptors. The drug also improved heart health markers. Experts believe retatrutide could be a game-changer for treating obesity and improving patient health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FJEq4Sa
via IFTTT

Read More

No cosmetic job with jabs, warns drug regulator CDSCO

The notice issued by the Central Drugs Standard Control Organisation (CDSCO) cites provisions of the Drugs and Cosmetics Act, 1940, and the Cosmetics Rules, 2020.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QKycW0G
via IFTTT

Read More

India plans national registry to track implantable medical devices and patients

India is set to launch a national registry for implantable medical devices. This initiative aims to track all devices and patients, ensuring only certified products are used. The registry will help curb overuse and fix accountability. It will also aid in identifying patients during recalls and tracking real-world safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hDYFcAn
via IFTTT

Read More

Chemists’ strike: CDSCO moves to prevent shortages

The CDSCO has advised state drug controllers to prevent drug scarcity during the AIOCD's proposed e-pharmacy strike on May 20. Measures include ensuring pharmacies remain open, coordinating with police, and negotiating to keep some shops operational to avoid medicine deserts. The government emphasizes uninterrupted public access to medicines as a top priority.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uMGf1Jj
via IFTTT

Read More

NCLAT allows Lyka Labs appeal; asks Modi Lifecare to pay Rs 63 lakh or face insolvency proceedings

The NCLAT has ruled in favor of Lyka Labs. It overturned a previous NCLT decision. Modi Lifecare Industries must now pay Rs 63 lakh within 30 days. Failure to pay will lead to insolvency proceedings against the company. The tribunal found that Modi Lifecare acknowledged its debt. This ruling stems from unpaid royalties under a technical guidance agreement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xt5aeV0
via IFTTT

Read More

Hearzap to acquire Amplifon India, expand network to 420 hearing care centres

Hearzap is acquiring Amplifon India in a deal that will significantly expand the company's presence across the country. The combined entity will operate approximately 420 hearing care centers. With this move, Hearzap is seeking to strengthen position in the organised hearing care market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XzVcGMp
via IFTTT

Read More

Rising input costs, export slump take a toll on drug companies' health

India's drug makers are facing a double blow. A weaker rupee makes imported raw materials more expensive. Global economic worries are also slowing down demand for Indian medicines abroad. This is squeezing profits for manufacturers. Companies are trying to focus on more profitable products. The situation presents a tough operating environment for the industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UQdLPIH
via IFTTT

Read More

AbbVie loses patent plea for Hep C drug

The Indian Patent Office has denied a secondary patent for AbbVie's Hepatitis C drug Maviret. This decision ensures continued access to affordable treatment for millions. The patent office refused the application after AbbVie failed to contest oppositions and chose to abandon it. This refusal prevents AbbVie from extending its patent monopoly by five years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NztJA5p
via IFTTT

Read More

Pharmacy associations to skip strike, major medicine disruption unlikely

A planned nationwide pharmacy strike on May 20 is unlikely to occur. Many retail pharmacy associations have withdrawn support. This follows assurances from the Central Drugs Standard Control Organisation that concerns about e-pharmacies are under review. Public interest and patient welfare are cited as reasons for declining the strike. Medicine availability is expected to remain uninterrupted.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pHjOo03
via IFTTT

Read More

Athena opens northeast India’s largest integrated psychiatric hospital in Guwahati

Athena Behavioral Health opens Northeast India's largest private psychiatric hospital in Guwahati. This marks their fifth hospital nationwide. The facility offers integrated treatment for mental health and substance use disorders. It aims to address the region's growing needs and shortage of structured care. The launch signifies a crucial step in making quality mental healthcare accessible in underserved areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wKiVf3e
via IFTTT

Read More

Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in Canada

Dr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providing treatment for type 2 diabetes. Canada is the first G7 nation to approve this medication. The launch follows a recent introduction in India. Dr Reddy's aims to expand access to these therapies globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WrVdyDF
via IFTTT

Read More

Why is healthcare AI stuck in pilot mode? UiPath has a straightforward answer

The gap between a successful AI pilot and a fully transformed healthcare operation is often wider than many organisations expect. UiPath bridges this gap by shifting the focus from simple automation to end-to-end orchestration

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uZbrVIa
via IFTTT

Read More

Roche brings 7-minute lung cancer shot to India

Roche Pharma India introduces a new injectable immunotherapy for lung cancer. This treatment takes only seven minutes, a significant reduction from hours-long infusions. It offers a less burdensome option for thousands of patients. The medicine, subcutaneous Tecentriq, is now approved for non-small cell lung cancer. This innovation aims to ease the strain on overcrowded cancer centers across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/E0hqXGM
via IFTTT

Read More

Drug regulator drafts guidelines on high-risk solvents after tainted syrup deaths in kids

India's drug regulator is creating new rules for dangerous solvents in children's medicines. This follows tragic deaths linked to contaminated cough syrups. Experts found these solvents can contain toxic impurities. The regulator is consulting with companies to assess current practices and explore safer alternatives. This action is vital after several children died from Indian-made cough syrups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OltYzga
via IFTTT

Read More

Zydus Lifesciences close to buying US oncology drug maker for $100 to 150 million: Sources

Indian drug maker Zydus Lifesciences is close to acquiring a US company. The deal is expected to be between $100 to $150 million. This acquisition will help Zydus build its own distribution network for anti-cancer drugs in the US. The target company also has its own pipeline of biologic drugs. A deal is anticipated soon.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2KAICpO
via IFTTT

Read More

Alzheimer's a key part of Eli Lilly's India specialty medicine push, says company's country head Winselow Tucker

Eli Lilly has introduced Lormalzi in India, a pioneering treatment for Alzheimer's that specifically targets amyloid plaques, a significant contributor to the condition. Unlike previous therapies that merely alleviate symptoms, this innovative medication aims to modify the disease itself.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T78HK0t
via IFTTT

Read More

Hospitals warn Central Government Health Scheme reimbursement cap may hurt cancer treatment

A major private hospital group warns of a crisis for advanced cancer patients under the Central Government Health Scheme. A reimbursement cap on life-saving immunotherapy drugs is creating financial strain for hospitals. This policy threatens patient access to essential treatments. The association has identified nine specific drugs that are now out of reach for many beneficiaries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4UdFNtG
via IFTTT

Read More

Eli Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity

Eli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The campaign aimed to reframe obesity as a chronic disease. It featured various media without naming specific products. Lilly cited regulatory uncertainty and conflicting guidance. The regulator's advisory prohibited indirect promotion of medicines. This pause impacts a public health initiative.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oqNlEpf
via IFTTT

Read More

Lord's Mark Industries Ltd. announces AI-supported Dialysis ecosystem launch

Lord's Mark Industries Ltd. has launched an integrated dialysis ecosystem in Ahmedabad, featuring the AI-driven Renalyx Machine. This CE-certified, India-engineered system, coupled with RenalOS and Aureoon, offers a Dialysis-as-a-Service model. It aims to provide accessible, affordable, and advanced renal care by eliminating capital investment for hospitals and focusing on patient-centric, continuous treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PVAFZfB
via IFTTT

Read More

Novartis expands India role in global drug development

Novartis is focusing on innovative medicines in India. The company is expanding its role in global drug development. Early-stage research is now happening in India. Novartis plans to launch more new medicines soon. This strategy reinforces its commitment to the Indian market and its significant employee base.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NHjQ6fq
via IFTTT

Read More

Biocon arm gets Health Canada nod for fungal infection treatment injection

Biocon Pharma Ltd has secured Health Canada approval for its micafungin for injection. This medication targets serious fungal infections in adults and children. It will be used for conditions like candidemia and esophageal candidiasis. The approval also covers prophylaxis in stem cell transplant patients. This marks a significant addition to Biocon's product offerings.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A9j4ngD
via IFTTT

Read More

Drugmakers must report safety data from launch date, not approval date: CDSCO

India's drug regulator has issued a new directive for pharmaceutical companies. Periodic Safety Update Reports for new drugs must now be submitted from the actual market launch date. This change aims to strengthen patient safety monitoring. Previously, reports were based on the regulatory approval date. The new rule ensures that real-world data from patients is included.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/grlCBG9
via IFTTT

Read More

India's hospital sector enters new growth cycle as AI and capacity expansion reshape care: Report

India's hospital sector is set for significant growth over the next decade. Demand is rising due to increased income, insurance, an aging population, and chronic diseases. Hospitals are expanding capacity to meet a critical bed shortage. Private insurance is growing, boosting revenue. This expansion offers substantial opportunities for investors and operators in the healthcare industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mWBKsXV
via IFTTT

Read More

EQT emerges sole bidder for OmniActive Health Technologies

Swedish investment powerhouse EQT is now leading the charge as the exclusive bidder for OmniActive Health Technologies, following the rejection of a competing offer from Temasek and Novo Holdings. Known for its robust presence in the nutraceutical industry, OmniActive is under the umbrella of TA Associates and has a strong export footprint in the United States.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/91pvszd
via IFTTT

Read More

MSD India ropes in Madhuri Dixit for cervical cancer awareness drive

US pharma major MSD has partnered with Bollywood actor Madhuri Dixit for a nationwide cervical cancer awareness program in India. The initiative aims to encourage conversations about women's preventive healthcare and prompt discussions with doctors regarding cervical cancer and its prevention. Digital films featuring Dixit have been released to amplify the campaign's reach.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EPz24lq
via IFTTT

Read More

Hantavirus outbreak on cruise ship: India monitors situation, no cases on Indian soil

The Union Health Ministry is monitoring hantavirus cases on the cruise ship MV Hondius, where three deaths and five confirmed infections have occurred. India has no domestic cases and its surveillance networks are active. The Andes strain, with limited human-to-human transmission, has been identified, and the WHO assesses the public health risk as low.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yKRBPXu
via IFTTT

Read More

India faces no immediate public health threat from hantavirus: NIV chief

Two Indian nationals aboard a cruise ship have reportedly contracted hantavirus. Indian health officials assure the public that these cases appear isolated. There is no immediate public health threat to India. Experts confirm hantavirus does not spread easily among people. India possesses adequate laboratory capacity for diagnosis. Standard rodent control and sanitation remain key preventive measures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gkVsenY
via IFTTT

Read More

Semaglutide race: Torrent grabs 38% market share

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of Novo Nordisk's patent for the innovator molecule in end-March. They generated about ₹44 crore in generic semaglutide sales in April.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MRljJ4P
via IFTTT

Read More

Dr Reddy's and Nestle Health Science strengthen presence in diabetes, obesity nutrition space

Dr Reddy's teams up with Nestle Health Science to introduce Celevida GLP+, a specialized supplement crafted for those navigating the challenges of GLP-1/GIP therapy for type 2 diabetes and obesity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/shVKNgM
via IFTTT

Read More

Venus Remedies expands Latin America presence with Argentina nod for antibiotic

Venus Remedies has received approval in Argentina for its antibiotic Ceftriaxone. This marks a significant step in the company's Latin America expansion. Argentina is a key market for critical care therapies. Ceftriaxone is vital for treating serious bacterial infections. This authorization strengthens Venus Remedies' global presence and commitment to accessible anti-infective treatments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x1SmKLv
via IFTTT

Read More

Sun Pharma gets relief in trademark case from High Court

The Bombay High Court has ruled in favour of Sun Pharmaceutical Industries. The court has restrained United Biotech from using a similar trademark. Sun Pharma's 'Octride' mark is protected. The dispute involves drugs for acromegaly and carcinoid tumours. The court found Sun Pharma had a stronger claim. This decision protects Sun Pharma's reputation and goodwill.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bCipSD7
via IFTTT

Read More

Kiran Mazumdar-Shaw picks niece Claire as successor at Biocon

Biocon's founder Kiran Mazumdar-Shaw has made a groundbreaking announcement, pledging her niece Claire Mazumdar as her heir apparent. The transition plan is designed for a slow handover while Mazumdar-Shaw remains at the helm.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VeLKuyd
via IFTTT

Read More

Emcure eyes India growth, global deals amid strong demand

Emcure Pharmaceuticals is boosting domestic expansion, R&D, and manufacturing. The company is also exploring acquisition opportunities in India and internationally. New products are expected to drive significant growth. Emcure's partnership with Novo Nordisk for GLP-1 therapies and a pipeline of complex injectables will support future momentum.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pz5h9Rg
via IFTTT

Read More

The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garage

Kiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who built the company from a garage into a global biotech leader, Kiran is ensuring continuity by handing over to a science-driven leader while remaining at the helm during the transition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5aD4IzM
via IFTTT

Read More

Biocon’s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: Report

Biocon founder Kiran Mazumdar-Shaw has announced her successor. Niece Claire Mazumdar will lead the company. Claire Mazumdar is the founder and CEO of Bicara Therapeutics. She holds advanced degrees and has prior industry experience. Biocon is also undergoing structural changes. The company focuses on biosimilars and integrating artificial intelligence. Other leadership transitions are also in progress across group companies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7IeS5jn
via IFTTT

Read More

Pharma exports surpass $31 billion in FY26 despite global headwinds

Indian pharmaceutical exports reached over $31 billion in FY26. March saw a significant 23% drop, primarily due to a slowdown in the United States and China. However, other markets like Africa and Oceania showed strong growth. Vaccines emerged as the fastest-growing export category. The industry is navigating challenges in key markets while exploring new growth avenues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Cm9AgZw
via IFTTT

Read More

Carlyle acquires Knack RCM and Equalize RCM to create an AI-native, global multi-specialty healthcare RCM platform

Global investment firm Carlyle has acquired a majority stake in US healthcare revenue cycle management providers Knack RCM and EqualizeRCM. This move aims to create a global, AI-native, multi-specialty RCM platform. The combined entity will leverage AI and global delivery to enhance operational scale and client outcomes, addressing critical financial risks for healthcare providers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iHPezoQ
via IFTTT

Read More

Two separate venues for pharma industry expos in Delhi-NCR

CPHI India and PMEC India are expanding their pharmaceutical expos to two venues in Delhi-NCR. This move aims to support the rapid growth of India's pharma sector. The events will offer greater business engagement and specialized networking. CPHI India will focus on ingredients and formulations. PMEC India will showcase machinery and manufacturing technologies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Uh081QY
via IFTTT

Read More

Bombay HC backs GSK in Paxil trademark row against Shreya Life Sciences

The Indian subsidiary of the UK-based GSK PLC had urged the court to cancel the mark used by the local company in pharmaceutical and medicinal preparations. It argued that despite getting the mark more than two decades ago, Shreya Life Sciences had never used it and hence, under Section 47 of the Trade Marks Act, the registration was liable to be removed from the register of trade marks on account of non-use.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9tGdrAP
via IFTTT

Read More

Aurobindo Pharma arm CuraTeQ gets Health Canada nod for biosimilar

Aurobindo Pharma announced a significant development today. Its subsidiary, CuraTeQ Biologics, has received a compliance notice from Health Canada for its cancer drug Bevqolva. This approval marks a crucial step for the bevacizumab biosimilar. Bevqolva is used to treat various cancers. Health Canada's nod confirms its safety and efficacy. This opens new avenues for cancer treatment in Canada.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4Zb1YWw
via IFTTT

Read More